Across TCGA pan-cancer cohorts, FAR1 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of FAR1’s most consistent transcriptional readouts.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where FAR1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types FAR1 is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.
CCRCC, LUAD, and LSCC are the cancer types where FAR1 tumor–normal differential expression is most reproducible.